ESR1 and breast carcinoma: In BrCa, amplification of the coactivator NCOA3/AIB1 (amplified in breast cancer 1) enhances estrogen receptor (ER) α activity and contributes to resistance toward selective estrogen receptor modulators such as tamoxifen (30).